Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics where Piers Gaunt is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Addition of zoledronic acid to consolidation chemotherapy in Ewing sarcoma-EURO EWING 2012 (EE2012): an international, open-label, randomised controlled phase III trial
Bernadette, B., Kirton, L., Marec-Bérard, P., Gaspar, N., Laurence, V., Martín-Broto, J., Gelderblom, H., Owens, C., Anderton, J., Strauss, S. J., Wingrove, J., Moroz, V., Whelan, J., Hjalgrim, L. L., Wheatley, K. & Gaunt, P., 20 May 2026, In: British Journal of Cancer. 134, 10, p. 1393-1402 10 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile15 Downloads (Pure) -
Promoting engagement in patient-initiated follow-up and self-care behaviours: acceptability of the 'ACT now & check-it-out' intervention for head and neck cancer (PETNECK2 study)
Matheson, L., Watson, E., Fulton-Lieuw, T., Mittal, S., Gaunt, P., Sissons, J., Liaskou, E., Gaunt, C., Nankivell, P., Mehanna, H. & Brett, J., 27 Feb 2026, In: BMJ Open. 16, 2, 11 p., e099993.Research output: Contribution to journal › Article › peer-review
Open AccessFile19 Downloads (Pure) -
1317O Results from CompARE phase III RCT: Neoadjuvant durvalumab plus chemoradiotherapy (CRT) followed by adjuvant durvalumab immunotherapy (IO) vs CRT alone in intermediate and high-risk oropharyngeal cancer (OPC)
Mehanna, H. M., Gaunt, P., Forster, M., Kong, A., Sen, M., Hartley, A., Geropantas, D., Moleron, R., Ghebretinsea, F., Gaunt, C., Humphreys, I., Nabi, Z., Garikipati, S., MacKenzie, J., Casswell, G., Aynsley, E., Ward, A., Sanghera, P., Paleri, V. & Nankivell, P., Sept 2025, In: Annals of Oncology. 36, Supplement 2, p. S768-S768 1 p.Research output: Contribution to journal › Abstract › peer-review
-
PRELIMINARY DOSE-VOLUME CONSTRAINTS PREDICTING SUBCUTANEOUS TISSUE FIBROSIS FOR LIMB SARCOMA USING THE VORTEX AND IMRIS TRIALS
Simoes, R., Seddon, B., Robinson, M. H., Shelly, S., Adedoyin, T., Dehbi, H.-M., Gaunt, P., Hughes, A., Miles, E., Hoskin, P., Harrington, K., Gulliford, S. & Miah, A. B., 21 Dec 2025, In: ESMO Rare Cancers. 4, C, p. 26-26 1 p., 100103.Research output: Contribution to journal › Abstract › peer-review
Open AccessFile1 Downloads (Pure) -
CompARE: study protocol for a phase III randomised controlled platform trial comparing alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer
Mehanna, H., Gaunt, P., Kong, A., Hartley, A., Sanghera, P., Forster, M., Sen, M., Paleri, V., Fong, C., Geropantas, D., Srinivasan, D., Garikipati, S., Moleron, R., Casswell, G., Aynsley, E., Ward, A., O'Toole, L., Mirza, A., Firth, C. & Humphreys, I. & 3 others, , Dec 2024, In: Trials. 25, 1, 17 p., 50.Research output: Contribution to journal › Article › peer-review
Open AccessFile65 Downloads (Pure)
-
Secondary Analysis of trial data to review the impact of (i) introducing 5+5 contouring and (ii) different chemotherapy regimens both on efficacy and swallowing outcomes using data from the phase III randomised CompARE trial
Gaunt, P. (Principal Investigator) & Mehanna, H. (Co-Investigator)
1/03/26 → 28/02/28
Project: Research
-
PETNECK2 - Radiomics in Outcome Predictive Models for Head and Neck Cancer
Mehanna, H. (Co-Investigator), Nankivell, P. (Principal Investigator), Karwath, A. (Co-Investigator) & Gaunt, P. (Co-Investigator)
1/10/25 → 31/08/27
Project: Other Government Departments
-
Biological studies in rEECur, an international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma
Gaunt, P. (Principal Investigator)
1/03/23 → 30/09/26
Project: Research
-
International clinical research programme to improve outcomes in newly diagnosed Ewing Sarcoma - Trial 1 (INTER-EWING-1)
Kirton, L. (Co-Investigator), Gaunt, P. (Principal Investigator) & Millen, G. (Co-Investigator)
Bayer, Bone Cancer Research Trust, Japan Agency For Medical Research And Development, Grupo Espanol De Investigatcion en Sarcoma (GEIS), Cancer Research UK, Fight Kids Cancer, SIOP Europe
1/12/21 → 30/11/32
Project: Research
-
FaR-RMS - An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma
Bowden, S. (Co-Investigator), Kearns, P. (Co-Investigator), Gatz, S. (Principal Investigator), Pirrie, S. (Researcher), Jackson, A. (Researcher), Liu, W. (Researcher) & Gaunt, P. (Researcher)
1/01/21 → 30/06/31
Project: EU
Activities
-
HALT Trial Data Monitoring Committee (Event)
Gaunt, P. (Advisor)
1 May 2018 → 30 Oct 2023Activity: Membership › Membership of working group or committee
-
NIMRAD Trial Data Monitoring Committee (Event)
Gaunt, P. (Advisor)
21 Nov 2017 → 30 Nov 2021Activity: Membership › Membership of working group or committee
-
NCRI Sarcoma Clinical Studies Group (External organisation)
Gaunt, P. (Advisor)
1 Nov 2017 → 1 Nov 2020Activity: Membership › Membership of working group or committee
-
Bone Cancer Research Trust (External organisation)
Gaunt, P. (Advisor)
Oct 2017 → 28 Feb 2025Activity: Membership › Advisory role
-
Prepare for Kidney Care Trial Data Monitoring Committee (Event)
Gaunt, P. (Advisor)
9 Dec 2016 → 30 Jun 2024Activity: Membership › Membership of working group or committee